Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
Virpax Pharmaceuticals Inc. has chosen Altasciences to conduct preclinical studies in support of their new drug, an intranasal spray, GCPQ, under the trade name, AnQlar. Click to read more.
Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI)
Altasciences is pleased to have completed the successful Phase I trial of Ischemix’ novel drug candidate, CMX-2043, for the treatment of acute traumatic brain injury (TBI), at our Montréal clinical facility.